Results 211 to 220 of about 52,007 (260)

Clinical and molecular data to predict flares in DMARD optimization in rheumatoid arthritis: a randomized, controlled, open-label, non-inferiority trial. [PDF]

Rheumatology (Oxford)
Blanco FJ, Galindo L, Acasuso B, Balboa-Barreiro V, Cañete JD, Cañete JD, Fernández-Gutiérrez B, González-Álvaro I, Pablos Álvarez JL, Bejerano-Herrería C, Silva-Díaz M, Rego-Perez I, Lourido L, Ruiz-Romero C, Uriarte-Ecenarro M, García-Vicuña R, Cuervo A, Ramírez J, Celis R, Rodríguez-Rodríguez L, Abasolo Alcázar L, Freites Nuñez D, Martín-López M, Toro-Santos FJ, Oreiro N.   +24 more
europepmc   +1 more source

Efficacy and safety of ciprofol for general anesthesia in pediatric strabismus correction surgery: a prospective, randomized, double-blind, non-inferiority study. [PDF]

Front Med (Lausanne)
Xu W, Xiao H, Shi X, Sun D, Xu H, Zhao C, Ji F.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Subgroup discovery in non‐inferiority trials

Statistics in Medicine, 2021
AbstractApproaches and guidelines for performing subgroup analysis to assess heterogeneity of treatment effect in clinical trials have been the topic of numerous papers in the statistical and clinical literature, but have been discussed predominantly in the context of conventional superiority trials.
Melissa J. Fazzari, Mimi Y. Kim
openaire   +2 more sources

The tyranny of non-inferiority trials

The Lancet Oncology
Opportunities to decrease the toxicity and cost of approved treatment regimens with lower dose, less frequent, or shorter duration alternative regimens have been limited by the perception that alternatives must be non-inferior to approved regimens.
Ian F, Tannock, Marc, Buyse, Mickael, De Backer, Helena, Earl, Daniel A, Goldstein, Mark J, Ratain, Leonard B, Saltz, Gabe S, Sonke, Garth W, Strohbehn   +8 more
openaire   +2 more sources

Non-inferiority Trials

Medizinische Monatsschrift fur Pharmazeuten, 2016
More and more clinical trials for new drugs are designed as non-inferiority trials. In order to assess the validity of these trials, however, a number of peculiarities have to be considered. This applies, e.g., to the exact definition of "non-inferiority" as well as to the data evaluation methods.
openaire   +3 more sources

Identification of the minimum non-inferior dose in a three-arm non-inferiority trial

Journal of the Korean Statistical Society, 2020
zbMATH Open Web Interface contents unavailable due to conflicting licenses.
Junjiang Zhong, Miin-Jye Wen, Siu Hung Cheung   +2 more
openaire   +2 more sources

Non-Inferiority Design

2018
This chapter discusses an interesting alternative to superiority RCT: the non-inferiority RCT. Non-inferiority trials are increasingly being used since superiority of effect is not the only factor in choosing a treatment option for patients. A typical motivation for a non-inferiority trial is when it is worthwhile to sacrifice a small fraction of ...
Raquel Ajub Moyses, Valeriam Angelim, Scott Evans, Rui Imamura, Felipe Fregni   +4 more
openaire   +1 more source

Assessing non‐inferiority: A combination approach

Statistics in Medicine, 2007
AbstractNon‐inferiority designs are growing in importance as a strategy for comparing new drugs with established therapies. Because it is not possible to show that a new drug and the established therapy have identical efficacy profiles, non‐inferiority trials are designed to demonstrate that the new drug is not inferior to an established drug (the ...
Ping, Gao, James H, Ware
openaire   +2 more sources